Logo
About usInnovation CMChallengesEuropaEntrepreneurshipR&D&I SearchAgentsEventsReports
en
QUINOLYLNITRONE DERIVATIVES FOR USE IN THE PREVENTION AND/OR TREATMENT OF HEARING LOSSCM Patents

[0000] The present invention provides derivatives of quinolylnitrones of formula I, wherein the meaning of the substituents is as described in the description, useful in treatment and/or prevention of hearing loss. [0000] Advantageously, these quinolylnitrones of formula (I) have a broad-spectrum effect, being efficient in the prevention and treatment of hearing loss regardless of its origin, whether caused by a physical agent, such as noise, or an ototoxic agent such as H<2>O<2>. [0000] <img class="EMIRef" id="574e5730-a1cb-4320-9d7e-7fcb4f07f980-EMI-C00001" />

Datos clave

CategoríaInvención

Índice de la ficha

Updated at
05/11/2026
Numero publicacion
EP.4309655.A1
Fecha publicacion
24/01/2024
Anio publicacion
2024
Numero solicitud
EP20220382706

En detalle

Reivindicaciones

1. A compound of formula I: <img class="EMIRef" id="b3da2419-78f2-480f-a0a4-efcd79a93b42-ib0002" /> wherein: R<1> represents a -C<1-5> alkyl or a known aromatic ring having 5 or 6 members selected from: -CH-, - CR<12>-, -O-, -N-, and -S-; each one of R<2> to R<7> independently represents -H, halogen, -OR<8> or -NHR<8>; each one R<8> independently represents -H or -C<1-5> alkyl, wherein the -C<1-5> alkyl is optionally substituted with one or more R<9>; each one R<9> independently represents halogen, -OH, -O-C<1-5> alkyl, -NH<2>, -NH(C<1-5> alkyl) or Cyi; and Cy<1> represents a known ring system having from 5 to 8 members, saturated, partially unsaturated or aromatic, optionally containing from 1 to 3 heteroatoms selected from N, O, Se and S, Cy<1> being optionally bound to the remaining structure through any C or N atom, and optionally substituted by one or more R<10>; each one R<10> independently represents a -C<1-5> alkyl optionally substituted with one or more R<11>; and each R<11> independently represents -C<2-5> alkynyl ,provided that at least two of the R<2> to R<7> are other than -H; for use in a method for the prevention and/or treatment of hearing loss. 2. The compound for use according to claim 1, wherein: R<1> represents a -C<1-5> alkyl or a known aromatic ring having 5 or 6 members selected from: -CH-, - CR<12>-, -O-, -N-, and -S-; each one of R<2> to R<7> independently represents -H, halogen, -OR<8> or -NHR<8>; and each one R<8> independently represents -H or -C<1-5> alkyl. 3. The compound of formula (I) for use according to any one the preceding claims, wherein R<1> represents C<1-5> alkyl. 4. The compound of formula (I) for use according to any one of the preceding claims, wherein R<1> represents tert-butyl. 5. The compound of formula (I) for use according to any one of the preceding claims, wherein each one R<2> a R<7> independently represents-H, halogen or -OR<8>. 6. The compound of formula (I) for use according to any one of the preceding claims, wherein R<3>, R<4>, R<6> and R<7> represent -H. 7. The compound of formula (I) for use according to any one of the preceding claims, wherein R<2> represents halogen. 8. The compound of formula (I) for use according to any one of the preceding claims, wherein R<2> represents chlorine. 9. The compound of formula (I) for use according to any one of the preceding claims, wherein R<5> -OR<8>. 10. The compound of formula (I) for use according to any of the preceding claims, wherein R<8> represents -C<1-5> alkyl. 11. The compound of formula (I) for use according to any of the preceding claims, which is (Z)-N-tert-butyl-1-(2-chloro-6-metoxiquinolin-3-yl)methanimine oxide (QN23). 12. The compound of formula (I) for use according to any of the preceding claims, wherein the hearing loss is due to a physical agent, such as noise. 13. The compound of formula (I) for use according to any of the preceding claims, wherein the hearing loss is due to exposure to an ototoxic agent. 14. The compound of formula (I) for use according to any of the preceding claims, wherein the method of preventing or treating comprises administering the compound before the exposition to the physical or ototoxic agent; or alternatively the compound is administered after the exposition to the physical or ototoxic agent; or alternatively the compound is administered both before and after the exposition to the physical or ototoxic agent. 15. The compound of formula (I) for use according to any of the preceding claims, which is administered in the form of a pharmaceutical composition which comprises at least one pharmaceutically acceptable adjuvant, excipient and/or vehicle; particularly in the form of an oral, topical, intratympanic, or parenteral administration; particularly in the form of otic drops.

Etiquetas

Inventores
MARCO CONTELLES, José LuisMarco Contelles José LuisMURILLO CUESTA, SilviaMurillo Cuesta SilviaRodríguez de la Rosa LourdesRODRÍGUEZ de la ROSA, LourdesVarela Nieto IsabelVARELA NIETO, IsabelALCÁZAR GONZÁLEZ, AlbertoAlcázar González Alberto
Solicitantes
Consejo Superior de Investigaciones CientíficasConsorcio Centro de Investigación Biomédica en RedUniversidad Autónoma de MadridFundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal
Clasificacion ipc
A61K 31/ 47 A IA61K 9/ 00 A IA61P 27/ 16 A I
Logo

Innovation CM
Challenges
Europa
Entrepreneurship
R&D&I Search
Agents
Events
Reports
About us
Contact
Give us your opinion
Cookies
Legal notice
Privacy

© Copyright Espacio Madrileño de Investigación e Innovación 2026